Brief: Abl Bio Announces Grabody-B Brain Delivery Platform License Agreement With GSK To Develop Novel Medicines For Neurodegenerative Diseases
07/04/2025 01:10
April 6 (Reuters) - ABL Bio Inc 298380.KQ: ABL BIO ANNOUNCES GRABODY-B BRAIN DELIVERY PLATFORM LICENSE AGREEMENT WITH GSK TO DEVELOP NOVEL MEDICINES FOR NEURODEGENERATIVE DISEASES ABL BIO INC - ABL BIO TO RECEIVE UP TO £77 MILLION IN UPFRONT AND NEAR-TERM PAYMENTS Source text: ID:nPn2m1T4Va Further company coverage: 298380.KQ ((Reuters.Briefs@thomsonreuters.com;))
Recent news on ABL Bio
See all newsBrief: Abl Bio Inc - Raises 37.7 Billion Won Worth Of New Shares
Brief: Abl Bio Announces Grabody-B Brain Delivery Platform License Agreement With GSK To Develop Novel Medicines For Neurodegenerative Diseases
Brief: Abl Bio Inc Signs Agreement With Intocell Inc To Use Its Antibody-Drug Conjugate Tech In Product Development
Brief: I-Mab And Abl Bio Announce Latest Updates Of Pd-L1 And 4-1BB Bispecific Antibody TJ-L14B/ABL503
Brief: Abl Bio To Acquire Real Estate Worth 65 Billion Won